Why the study?
Does a paclitaxel-eluting TAXUS moderate-release stent reduce MACE and revascularization rates compared to a bare metal stent in patients with long, complex coronary artery lesions?
Does a paclitaxel-eluting TAXUS moderate-release stent reduce MACE and revascularization rates compared to a bare metal stent in patients with long, complex coronary artery lesions?
In patients with long, complex coronary lesions, the paclitaxel-eluting TAXUS MR stent reduced target lesion revascularization at 5 years compared to bare metal stents, without a significant difference in overall MACE.
No takes yet. Share an insight, caveat, or question.
Supports TAXUS for fewer repeat procedures in complex lesions; extends durability of paclitaxel-eluting stent benefits to 5 years.
Grube et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: